This article was originally published on 2 September 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. The subsequent MERS outbreak in South Korea in 2015 and the COVID-19 pandemic in 2020 lent new significance to early coronavirus analysis of this kind.
Scale of the outbreak
As of 30 August 2013, the World Health Organisation had recorded 108 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV), including 50 deaths - a case fatality rate of approximately 50%, comparable to avian influenza H5N1. Cases were concentrated in four countries around the Arabian Peninsula: Saudi Arabia (where most deaths occurred), UAE, Qatar and Jordan, with imported cases in UK and France. No US cases had been documented.
Approximate case fatality rate of MERS-CoV as of August 2013, significantly higher than SARS (~9.6%) or seasonal influenza
Transmission and the animal reservoir
MERS-CoV is a novel beta RNA coronavirus most closely related to bat coronaviruses (HKU4 and HKU5). Emerging research demonstrated high titres of neutralising antibodies against MERS-CoV in dromedary camels, suggesting this species may serve as an intermediate host - explaining the specific geographic concentration of cases around the Arabian Peninsula. Blocking zoonotic transmission from camels to humans could prove the most cost-effective control intervention if confirmed.
Pandemic potential assessment
WHO's emergency committee decided not to declare MERS-CoV a Public Health Emergency of International Concern in July 2013. Studies showed MERS-CoV had not spread as rapidly or as widely as SARS, and adaptation to humans appeared to be proceeding slowly. The virus appeared to lack the transmissibility to sustain large community outbreaks in settings with adequate healthcare infection control.
"In the past decade we have seen H3N2, H1N1, SARS, H7N9 and now MERS-CoV. As long as man lives in close proximity with animals, and viruses maintain their ability to mutate, we must remain ever vigilant."
Vaccine and therapeutic development
No specific antiviral had shown efficacy against MERS-CoV. The US CDC had disclosed early discussions with an undisclosed developer on vaccine candidates, and much could be learned from prior SARS vaccine work - though no SARS product was ever licensed. The US Obama Administration classified MERS-CoV as a public health threat, enabling the FDA to expedite approval of diagnostics and treatments.